Skip to main content
Top
Published in: Inflammation Research 8/2016

01-08-2016 | Original Research Paper

The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis

Authors: Houda Benabdoune, Elsa-Patricia Rondon, Qin Shi, Julio Fernandes, Pierre Ranger, Hassan Fahmi, Mohamed Benderdour

Published in: Inflammation Research | Issue 8/2016

Login to get access

Abstract

Objective and design

Resolvin D1 (RvD1), an omega-3 fatty acid derivative, has shown remarkable properties in resolving inflammation, promoting tissue repair and preserving tissue integrity. In this study, we investigated RvD1 effects on major processes involved in osteoarthritis (OA) pathophysiology.

Materials and methods

Human OA chondrocytes were treated with either 1 ng/ml interleukin-1β (IL-1β) or 20 μM 4-hydroxynonenal (HNE), then treated or not with increased concentrations of RvD1 (0–10 μM). RvD1 levels were measured by enzyme immunoassay in synovial fluids from experimental dog model of OA and sham operated dogs obtained from our previous study. Cell viability was evaluated by 3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-SH-tetrazolium bromide assay. Parameters related to inflammation, catabolism and apoptosis were determined by enzyme-linked immunosorbent assay, Western blotting, and quantitative polymerase chain reaction. Glutathione (GSH) was assessed by commercial kit. The activation of mitogen-activated protein kinases and nuclear factor-kappaB (NF-κB) pathways was evaluated by Western blot.

Results

We showed that RvD1 levels were higher in synovial fluids from OA joint compared to controls. In OA human chondrocytes, we demonstrated that RvD1 was not toxic up to 10 μM and stifled IL-1β-induced cyclooxygenase 2, prostaglandin E2, inducible nitric oxide synthase, nitric oxide, and matrix metalloproteinase-13. Our study of signalling pathways revealed that RvD1 suppressed IL-1β-induced activation of NF-κB/p65, p38/MAPK and JNK1/2. Moreover, RvD1 prevented HNE-induced cell apoptosis and oxidative stress, as indicated by inactivation of caspases, inhibition of lactate dehydrogenase release, and increased levels of Bcl2 and AKT, as well as GSH.

Conclusion

This is the first in vitro study demonstrating the beneficial effect of RvD1 in OA. That RvD1 abolishing a number of factors known to be involved in OA pathogenesis renders it a clinically valuable agent in prevention of the disease.
Literature
2.
go back to reference Bombardier C. The impact of arthritis in Canada. Today and over the next 30 years. Arthritis Alliance Canada. 2011;606:1–52. Bombardier C. The impact of arthritis in Canada. Today and over the next 30 years. Arthritis Alliance Canada. 2011;606:1–52.
3.
go back to reference Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castrogiovanni P, Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci. 2015;16:6093–112.CrossRefPubMedPubMedCentral Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castrogiovanni P, Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci. 2015;16:6093–112.CrossRefPubMedPubMedCentral
4.
go back to reference Ziskoven C, Jager M, Kircher J, Patzer T, Bloch W, Brixius K, Krauspe R. Physiology and pathophysiology of nitrosative and oxidative stress in osteoarthritic joint destruction. Can J Physiol Pharmacol. 2011;89:455–6.CrossRefPubMed Ziskoven C, Jager M, Kircher J, Patzer T, Bloch W, Brixius K, Krauspe R. Physiology and pathophysiology of nitrosative and oxidative stress in osteoarthritic joint destruction. Can J Physiol Pharmacol. 2011;89:455–6.CrossRefPubMed
6.
go back to reference Vaillancourt F, Fahmi H, Shi Q, Lavigne P, Ranger P, Fernandes JC, et al. 4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Res Ther. 2008;10:R107.CrossRefPubMedPubMedCentral Vaillancourt F, Fahmi H, Shi Q, Lavigne P, Ranger P, Fernandes JC, et al. 4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Res Ther. 2008;10:R107.CrossRefPubMedPubMedCentral
7.
go back to reference Lotz M, Hashimoto S, Kuhn K. Mechanisms of chondrocyte apoptosis. Osteoarthr Cartil. 1999;7:389–91.CrossRefPubMed Lotz M, Hashimoto S, Kuhn K. Mechanisms of chondrocyte apoptosis. Osteoarthr Cartil. 1999;7:389–91.CrossRefPubMed
8.
go back to reference Takada K, Hirose J, Yamabe S, Uehara Y, Mizuta H. Endoplasmic reticulum stress mediates nitric oxide-induced chondrocyte apoptosis. Biomed Rep. 2013;1:315–9.PubMedPubMedCentral Takada K, Hirose J, Yamabe S, Uehara Y, Mizuta H. Endoplasmic reticulum stress mediates nitric oxide-induced chondrocyte apoptosis. Biomed Rep. 2013;1:315–9.PubMedPubMedCentral
9.
go back to reference Bentz M, Zaouter C, Shi Q, Fahmi H, Moldovan F, Fernandes JC, et al. Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. J Cell Biochem. 2012;113:2256–7.CrossRefPubMed Bentz M, Zaouter C, Shi Q, Fahmi H, Moldovan F, Fernandes JC, et al. Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. J Cell Biochem. 2012;113:2256–7.CrossRefPubMed
10.
go back to reference Mongkhon JM, Thach M, Shi Q, Fernandes JC, Fahmi H, Benderdour M. Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflamm Res. 2014;63:691–701.CrossRefPubMed Mongkhon JM, Thach M, Shi Q, Fernandes JC, Fahmi H, Benderdour M. Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflamm Res. 2014;63:691–701.CrossRefPubMed
12.
go back to reference Henrotin Y, Marty M, Appelboom T, Avouac B, Berenbaum F, Briole V, et al. Traduction française des recommandations de l’Osteoarthritis Research Society International (OARSI) sur la prise en charge de la gonarthrose et de la coxarthrose. Revue du rhumatisme. 2009;76:279–88.CrossRef Henrotin Y, Marty M, Appelboom T, Avouac B, Berenbaum F, Briole V, et al. Traduction française des recommandations de l’Osteoarthritis Research Society International (OARSI) sur la prise en charge de la gonarthrose et de la coxarthrose. Revue du rhumatisme. 2009;76:279–88.CrossRef
13.
go back to reference Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil. 2007;15:981–1000.CrossRefPubMed Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil. 2007;15:981–1000.CrossRefPubMed
14.
go back to reference Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–62.CrossRefPubMed Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–62.CrossRefPubMed
15.
go back to reference Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–7.CrossRefPubMed Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–7.CrossRefPubMed
16.
go back to reference Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–204.CrossRefPubMedPubMedCentral Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–204.CrossRefPubMedPubMedCentral
17.
go back to reference Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612–9.CrossRefPubMed Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612–9.CrossRefPubMed
18.
go back to reference Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004;73:155–72.CrossRefPubMed Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004;73:155–72.CrossRefPubMed
19.
21.
go back to reference Norling LV, Perretti M. The role of omega-3 derived resolvins in arthritis. Curr Opin Pharmacol. 2013;13:476–81.CrossRefPubMed Norling LV, Perretti M. The role of omega-3 derived resolvins in arthritis. Curr Opin Pharmacol. 2013;13:476–81.CrossRefPubMed
22.
go back to reference Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181:8677–87.CrossRefPubMedPubMedCentral Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181:8677–87.CrossRefPubMedPubMedCentral
24.
go back to reference Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M. Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum. 2006;54:271–81.CrossRefPubMed Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M. Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum. 2006;54:271–81.CrossRefPubMed
25.
go back to reference Shi Q, Abusarah J, Zaouter C, Moldovan F, Fernandes JC, Fahmi H, et al. New evidence implicating 4-hydroxynonenal in the pathogenesis of osteoarthritis in vivo. Arthritis Rheumatol. 2014;66:2461–71.CrossRefPubMed Shi Q, Abusarah J, Zaouter C, Moldovan F, Fernandes JC, Fahmi H, et al. New evidence implicating 4-hydroxynonenal in the pathogenesis of osteoarthritis in vivo. Arthritis Rheumatol. 2014;66:2461–71.CrossRefPubMed
26.
go back to reference El-Bikai R, Welman M, Margaron Y, Cote JF, Macqueen L, Buschmann MD, et al. Perturbation of adhesion molecule-mediated chondrocyte-matrix interactions by 4-hydroxynonenal binding: implication in osteoarthritis pathogenesis. Arthritis Res Ther. 2010;12:R201.CrossRefPubMedPubMedCentral El-Bikai R, Welman M, Margaron Y, Cote JF, Macqueen L, Buschmann MD, et al. Perturbation of adhesion molecule-mediated chondrocyte-matrix interactions by 4-hydroxynonenal binding: implication in osteoarthritis pathogenesis. Arthritis Res Ther. 2010;12:R201.CrossRefPubMedPubMedCentral
27.
go back to reference Abella V, Santoro A, Scotece M, Conde J, Lopez-Lopez V, Lazzaro V, Gomez-Reino JJ, Meli R, Gualillo O. Non-dioxin-like polychlorinated biphenyls (PCB 101, PCB 153 and PCB 180) induce chondrocyte cell death through multiple pathways. Toxicol Lett. 2015;234:13–9.CrossRefPubMed Abella V, Santoro A, Scotece M, Conde J, Lopez-Lopez V, Lazzaro V, Gomez-Reino JJ, Meli R, Gualillo O. Non-dioxin-like polychlorinated biphenyls (PCB 101, PCB 153 and PCB 180) induce chondrocyte cell death through multiple pathways. Toxicol Lett. 2015;234:13–9.CrossRefPubMed
28.
go back to reference Sakata S, Hayashi S, Fujishiro T, Kawakita K, Kanzaki N, Hashimoto S, et al. Oxidative stress-induced apoptosis and matrix loss of chondrocytes is inhibited by eicosapentaenoic acid. J Orthop Res. 2015;33:359–65.CrossRefPubMed Sakata S, Hayashi S, Fujishiro T, Kawakita K, Kanzaki N, Hashimoto S, et al. Oxidative stress-induced apoptosis and matrix loss of chondrocytes is inhibited by eicosapentaenoic acid. J Orthop Res. 2015;33:359–65.CrossRefPubMed
29.
go back to reference Page CJ, Hinman RS, Bennell KL. Physiotherapy management of knee osteoarthritis. Int J Rheum Dis. 2011;14:145–51.CrossRefPubMed Page CJ, Hinman RS, Bennell KL. Physiotherapy management of knee osteoarthritis. Int J Rheum Dis. 2011;14:145–51.CrossRefPubMed
30.
go back to reference Laev SS, Salakhutdinov NF. Anti-arthritic agents: progress and potential. Bioorg Med Chem. 2015;23:3059–80.CrossRefPubMed Laev SS, Salakhutdinov NF. Anti-arthritic agents: progress and potential. Bioorg Med Chem. 2015;23:3059–80.CrossRefPubMed
31.
go back to reference Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J. 2011;437:185–7.CrossRefPubMedPubMedCentral Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J. 2011;437:185–7.CrossRefPubMedPubMedCentral
32.
go back to reference Jung TW, Hwang HJ, Hong HC, Choi HY, Yoo HJ, Baik SH, et al. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells. Mol Cell Endocrinol. 2014;391:30–40.CrossRefPubMed Jung TW, Hwang HJ, Hong HC, Choi HY, Yoo HJ, Baik SH, et al. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells. Mol Cell Endocrinol. 2014;391:30–40.CrossRefPubMed
33.
go back to reference Lehmann C, Homann J, Ball AK, Blocher R, Kleinschmidt TK, Basavarajappa D, et al. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein. FASEB J. 2015 [Epub ahead of print]. Lehmann C, Homann J, Ball AK, Blocher R, Kleinschmidt TK, Basavarajappa D, et al. Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein. FASEB J. 2015 [Epub ahead of print].
34.
go back to reference Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol. 2013;4:13.PubMedPubMedCentral Hong S, Lu Y. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol. 2013;4:13.PubMedPubMedCentral
35.
go back to reference Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol. 2006;177:5902–11.CrossRefPubMed Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol. 2006;177:5902–11.CrossRefPubMed
36.
go back to reference Leigh NJ, Nelson JW, Mellas RE, Aguirre A, Baker OJ. Expression of resolvin D1 biosynthetic pathways in salivary epithelium. J Dent Res. 2014;93:300–5.CrossRefPubMedPubMedCentral Leigh NJ, Nelson JW, Mellas RE, Aguirre A, Baker OJ. Expression of resolvin D1 biosynthetic pathways in salivary epithelium. J Dent Res. 2014;93:300–5.CrossRefPubMedPubMedCentral
37.
go back to reference Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025–7.CrossRefPubMedPubMedCentral Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025–7.CrossRefPubMedPubMedCentral
38.
go back to reference Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323–4.CrossRefPubMed Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323–4.CrossRefPubMed
39.
go back to reference Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta. 2012;1821:1415–24.CrossRefPubMedPubMedCentral Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta. 2012;1821:1415–24.CrossRefPubMedPubMedCentral
40.
go back to reference Chabane N, Zayed N, Benderdour M, Martel-Pelletier J, Pelletier JP, et al. Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Res Ther. 2009;11:R44.CrossRefPubMedPubMedCentral Chabane N, Zayed N, Benderdour M, Martel-Pelletier J, Pelletier JP, et al. Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Res Ther. 2009;11:R44.CrossRefPubMedPubMedCentral
41.
go back to reference Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest. 1997;99:1231–7.CrossRefPubMedPubMedCentral Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest. 1997;99:1231–7.CrossRefPubMedPubMedCentral
42.
go back to reference Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1998;10:263–8.CrossRefPubMed Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1998;10:263–8.CrossRefPubMed
43.
go back to reference Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997;99:1534–5.CrossRefPubMedPubMedCentral Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997;99:1534–5.CrossRefPubMedPubMedCentral
44.
go back to reference Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998;273:27467–73.CrossRefPubMed Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998;273:27467–73.CrossRefPubMed
45.
go back to reference Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003;33:155–7.CrossRefPubMed Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003;33:155–7.CrossRefPubMed
46.
go back to reference Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527:440–7.CrossRefPubMedPubMedCentral Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527:440–7.CrossRefPubMedPubMedCentral
47.
go back to reference Wang L, Ma T, Zheng Y, Lv S, Li Y, Liu S. Diosgenin inhibits IL-1beta-induced expression of inflammatory mediators in human osteoarthritis chondrocytes. Int J Clin Exp Pathol. 2015;8:4830–6.PubMedPubMedCentral Wang L, Ma T, Zheng Y, Lv S, Li Y, Liu S. Diosgenin inhibits IL-1beta-induced expression of inflammatory mediators in human osteoarthritis chondrocytes. Int J Clin Exp Pathol. 2015;8:4830–6.PubMedPubMedCentral
48.
go back to reference Xu MX, Tan BC, Zhou W, Wei T, Lai WH, Tan JW, et al. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther. 2013;19:235–43.CrossRefPubMed Xu MX, Tan BC, Zhou W, Wei T, Lai WH, Tan JW, et al. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther. 2013;19:235–43.CrossRefPubMed
49.
go back to reference Lee HN, Kundu JK, Cha YN, Surh YJ. Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor-alpha expression. J Cell Sci. 2013;126:4037–47.CrossRefPubMed Lee HN, Kundu JK, Cha YN, Surh YJ. Resolvin D1 stimulates efferocytosis through p50/p50-mediated suppression of tumor necrosis factor-alpha expression. J Cell Sci. 2013;126:4037–47.CrossRefPubMed
50.
go back to reference Wang B, Gong X, Wan JY, Zhang L, Zhang Z, Li HZ, et al. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm Pharmacol Ther. 2011;24:434–41.CrossRefPubMed Wang B, Gong X, Wan JY, Zhang L, Zhang Z, Li HZ, et al. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm Pharmacol Ther. 2011;24:434–41.CrossRefPubMed
51.
go back to reference Gilbert K, Bernier J, Bourque-Riel V, Malick M, Rousseau G. Resolvin D1 reduces infarct size through a phosphoinositide 3-kinase/protein kinase B mechanism. J Cardiovasc Pharmacol. 2015;66:72–9.CrossRefPubMed Gilbert K, Bernier J, Bourque-Riel V, Malick M, Rousseau G. Resolvin D1 reduces infarct size through a phosphoinositide 3-kinase/protein kinase B mechanism. J Cardiovasc Pharmacol. 2015;66:72–9.CrossRefPubMed
52.
go back to reference Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil. 2003;11:747–55.CrossRefPubMed Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil. 2003;11:747–55.CrossRefPubMed
53.
go back to reference Ahmad R, Sylvester J, Ahmad M, Zafarullah M. Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytes. Arch Biochem Biophys. 2011;507:350–5.CrossRefPubMed Ahmad R, Sylvester J, Ahmad M, Zafarullah M. Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytes. Arch Biochem Biophys. 2011;507:350–5.CrossRefPubMed
54.
go back to reference Kar S, Subbaram S, Carrico PM, Melendez JA. Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir Physiol Neurobiol. 2010;174:299–306.CrossRefPubMedPubMedCentral Kar S, Subbaram S, Carrico PM, Melendez JA. Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir Physiol Neurobiol. 2010;174:299–306.CrossRefPubMedPubMedCentral
55.
go back to reference Tiku ML, Allison GT, Naik K, Karry SK. Malondialdehyde oxidation of cartilage collagen by chondrocytes. Osteoarthr Cartil. 2003;11:159–66.CrossRefPubMed Tiku ML, Allison GT, Naik K, Karry SK. Malondialdehyde oxidation of cartilage collagen by chondrocytes. Osteoarthr Cartil. 2003;11:159–66.CrossRefPubMed
56.
go back to reference Cox R Jr, Phillips O, Fukumoto J, Fukumoto I, Parthasarathy PT, Arias S, et al. Enhanced resolution of hyperoxic acute lung injury as a result of aspirin triggered resolvin D1 treatment. Am J Respir Cell Mol Biol. 2015;53:422–35.CrossRefPubMed Cox R Jr, Phillips O, Fukumoto J, Fukumoto I, Parthasarathy PT, Arias S, et al. Enhanced resolution of hyperoxic acute lung injury as a result of aspirin triggered resolvin D1 treatment. Am J Respir Cell Mol Biol. 2015;53:422–35.CrossRefPubMed
Metadata
Title
The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis
Authors
Houda Benabdoune
Elsa-Patricia Rondon
Qin Shi
Julio Fernandes
Pierre Ranger
Hassan Fahmi
Mohamed Benderdour
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 8/2016
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-016-0946-x

Other articles of this Issue 8/2016

Inflammation Research 8/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine